-
Mary’s Lung Cancer Story: It Doesn’t Stop You From Living
For people diagnosed with lung cancer, receiving a second opinion can be an important step in confirming treatment decisions or opting for a new approach to treatment. In Mary Burlie’s case, getting a second opinion changed everything. Although her first oncologist did not believe that Mary’s lung cancer had a treatable biomarker, a second opinion…
-
FDA Approves Rybrevant (amivantamab-vmjw) for Non-small Cell Lung Cancer with EGFR-Exon 20 Mutation
On March 1, 2024, the U.S. Food and Drug Administration (FDA) approved the drug Rybrevant (amivantamab-vmjw) to be given in combination with carboplatin and pemetrexed in the first lining setting for people with metastatic non-small cell lung cancer (NSCLC) with an EGFR exon 20 mutation. They also announced traditional approval for Rybrevant (amivantamab-vmjw) to be…
-
GO2 for Lung Cancer Holds Lung Cancer Voices Summit on Capitol Hill to Advocate for Increased Research Funding for the Leading Cause of Cancer Death
More than 230,000 Americans will die of lung cancer this year WASHINGTON, March 4, 2024 – On Tuesday, March 5 GO2 for Lung Cancer (GO2) will host more than 200 supporters on Capitol Hill to educate members of Congress on the urgent needs of the lung cancer community. GO2’s Lung Cancer Voices Summit participants hope to…
-
Meet HealthUnlocked’s “Denzie:” Celebrating 13 Years of Survival
.fusion-body .fusion-builder-column-0{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-0 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1024px) {.fusion-body .fusion-builder-column-0{width:100% !important;order : 0;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-0{width:100% !important;order : 0;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right :…
-
Ask the Experts: What’s New in SCLC Research?
Question: I have small cell lung cancer (SCLC). What’s new in research related to SCLC? What should I know about clinical trials? (Answered by Dr. Jacob Sands from Dana-Farber Cancer Institute during his appearance on the Lung Cancer Living Room. It has been edited slightly for this use.) Answer: There is a lot of research…
-
Finding Hope in an ALK+ Diagnosis
Craig S. lives in Washington, D.C., with his wife, Lydia, and daughter, Lola, who is a freshman at Tulane University. He has worked in software sales and sales leadership since getting his MBA from George Washington University. He enjoys rooting for the Washington Nationals, cooking, experimenting with cocktail recipes, and spending time with his friends…
-
Do I Need Another Test? The Importance of Repeat Biomarker Testing in NSCLC
Author: Brittney Nichols, MPH, BSN-RN, Senior Specialist, Science & Research, GO2 for Lung Cancer Biomarker testing is an important part of the cancer diagnosis and care continuum. For almost all people diagnosed with non-small cell lung cancer (NSCLC) biomarker testing is considered a routine part of guideline-concordant care (the minimal treatment patients should receive according…
-
Unleashing Precision: AI’s Promising Role in Revolutionizing Lung Cancer Care
Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer You’ve likely started to see artificial intelligence (AI) being used more and more in your everyday life. While the benefits and challenges of using AI in fields such as healthcare must be carefully considered, we asked one of the most popular…
-
Antibody-Drug Conjugates (ADCs): A Promising Treatment for Lung Cancer
Author: Renee Botello, MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer With decades of research and advances in precision medicine, scientists continue to broaden the treatment standards and options for patients with non-small cell lung cancer (NSCLC). By developing new ways, strategies, and innovative research techniques, this rapid development leads to a future direction…
-
Nicole Phipps Is Spearheading GO2’s Efforts to Confront Lung Cancer Every Day for Everyone
Nicole Phipps took a job working in lung cancer advocacy almost thirteen years ago to honor her grandfather, a lung cancer survivor. Now she’s applying that passion—and her considerable skills—to ensure that vital lung cancer education, support, connection, and community are accessible to all. Meet GO2 for Lung Cancer’s senior director of support programs and…